WO2021152393A1 - Compositions bioluminescentes et leurs utilisations - Google Patents

Compositions bioluminescentes et leurs utilisations Download PDF

Info

Publication number
WO2021152393A1
WO2021152393A1 PCT/IB2021/000038 IB2021000038W WO2021152393A1 WO 2021152393 A1 WO2021152393 A1 WO 2021152393A1 IB 2021000038 W IB2021000038 W IB 2021000038W WO 2021152393 A1 WO2021152393 A1 WO 2021152393A1
Authority
WO
WIPO (PCT)
Prior art keywords
coelenterazine
compound
conjugate
alkylene
antibody
Prior art date
Application number
PCT/IB2021/000038
Other languages
English (en)
Inventor
Elena A. Goun
Pavlo Khodakivskyi
Manuel DREFAHL
Aleksey Yevtodiyenko
Hacer Karatas
Original Assignee
Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Dar-Tto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Dar-Tto filed Critical Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Dar-Tto
Publication of WO2021152393A1 publication Critical patent/WO2021152393A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material

Definitions

  • This disclosure relates to a new bioluminescent reporter assay technology that can enable real time kinetic capacity and high sensitivity for imaging and quantification of uptake of biomolecules inside the cytosolic compartment of the cell. Since most of the biological targets are located inside the cells and require entry in the cytosol, this assay represents a valuable tool for drug discovery of novel therapeutics and understanding of basic mechanism of cell entry of biologically active biomolecules.
  • the biomolecules suitable for this assay include, but not limit, to the following classes of biomolecules: small molecule drugs, vitamins, metabolites (lipids, glucose, etc.), peptides, antibodies, antibody drug conjugates, proteins, nanoparticles, viruses, cells, and bacteria.
  • the assay is suitable for both in vitro (ex. live cells) and in vivo (live animals) applications enabling important aspect of drug discovery. This assay is termed in this disclosure as Bioluminescence Imaging of Cellular Uptake (BL-ICU).
  • Bioly active compounds such as small molecules, peptides, antibodies and antibodies drug conjugates constitute a dynamic and rapidly expanding class of biotherapeutics capable of targeting multiple human disease indications including cardiovascular, respiratory, autoimmune and oncology disorders.
  • small molecules represent the most common class of pharmaceuticals.
  • the majority of small molecule drug targets are inside the cells and therefore efficiency to cross cellular barriers is an important parameter for their biological activity.
  • Peptide therapeutics is another important class of drugs that play a central role in medical practice. Over 60 peptide drugs have been approved in the United States and other major markets in the last few years. They have many advantages over small-molecule drugs such as low toxicity and fast clearance. However, the major obstacle for the peptidic drug development is their high polarity that is the main reason for their low levels of cell permeability.
  • Nanoparticle drug delivery is a novel technologies that utilizes nanoparticles for the targeted delivery followed by controlled release of drugs.
  • the main advantages of nanoparticles is their high drug load capacity, targeted delivery to the tissues of interest (ex. cancer) and their ability to facilitate intracellular uptake.
  • biodistribution and accumulation As well as intracelluar drug delivery. Due to the lack of existing tools for quantification of intracellular drug release, the development of a nanoparticle drug delivery system remains to be a long and expensive process.
  • ADCs Antibody Drug Conjugates
  • These ADCs seek to combine - through a physical linkage - the extraordinarily specificity and disease targeting potential of mAbs with the potent, but indiscriminate, cell killing activity of various well-characterized natural and synthetic toxin molecules (e.g. aurostatins, maytansinoids). It is widely considered that specific targeting of such chemotherapeutic ‘payloads’ to sites of oncological disease, may offer significant advantages with regard to treatment efficacy, side-effect avoidance and general patient outcomes.
  • mAbs for ADC development ideally requires knowledge of: a) the affinity and selectivity of mAb binding to a target cell antigen (more specifically, an epitope), b) the extent to which the mAb-antigen complex is internalized (endocytosed), c) the extent to which the mAb is then degraded within the lytic compartments of the cell, and/or d) the extent to which the resultant lytic fragments (containing the toxin ‘payload‘) are trafficked into the cytosolic compartment of the cell (where the ‘payload‘ will exert its cytotoxicity).
  • a means to comprehensively monitor or observe these sequentially linked processes would be considered a highly desirable and enabling ADC platform capability.
  • This application discloses an enabling, scalable reporter assay technology that is developed by combining chemical and biochemical innovation.
  • This reporter assay can provide real time kinetic data for the uptake and processing of prospective ADC candidate Abs as well as other therapeutic molecules such as small-molecule drugs, peptides, metabolites, vitamins, nanoparticles and viruses that rely on cellular internalization.
  • the assay can, in addition, yield information on the internalization behavior of different cell-surface antigens.
  • This assay named Bioluminescence Imaging of Cellular Uptake (BL-ICU), relies on labeling biomolecules through a linker such as a disulfide bond with a novel luciferin molecule (ex. Thiol Tag Luciferin (TT-Luc), FIG. 1).
  • the labeling can also be done via chemical conjugation to amines, that relies on the same reported molecule (ex. Amino Tag Luciferin (AT-Luc), FIG. 1).
  • the linker such as the disulfide bond is cleaved to release the luciferin derivative, a process that can be monitored in cells expressing luciferase enzyme.
  • BL-ICU assay provides significant advantages over regular caging strategy.
  • Amino Tag Luciferin (AT-Luc) and Thiol Tag Luciferin (TT-Luc) produce bright light upon reaction with luciferase enzyme and possess unprecedented stability producing no background in biological environment. They can be attached to a wide variety of biomolecules using easy-to-perform chemistry resulting in stable conjugates. That makes them excellent tags for studies of biological uptake.
  • No similar molecules are known in the literature as the general “believe” that luciferin has to be free to produce light (the tag compounds provided herein have luciferin tagged with special non-releasable cytosol-environment sensitive linker).
  • BL-ICU assay is highly flexible, easy to apply and can be readily adapted to early drug discovery platforms.
  • L is a bioluminescent reporter or a pro-luminescent moiety.
  • Formula II wherein B comprises a biomolecule and L is a bioluminescent reporter or a pro-luminescent moiety.
  • L is a bioluminescent reporter or a pro-luminescent moiety.
  • X is an alkylene
  • Z is an optionally substituted alkyl, an optionally substituted
  • L _g _ I aryl, an optionally substituted heteroaryl, , or 1 ; wherein Y is an optionally substituted alkylene, optionally substituted cycloalkylene, optionally substituted arylene, or polyethylene glycol PEGn, where n l-50; and A is selected from the group consisting of , wherein R is optionally substituted alkyl.
  • X is an alkylene and L is a bioluminescent reporter or a pro-luminescent moiety.
  • a method for preparing a conjugate of Formula II or IV comprising incubating a biomolecule with a compound of Formula I or III, respectviely.
  • a method for detecting cellular uptake and processing of a biomolecule comprising contacting a sample with a conjugate of Formula II or IV.
  • the sample comprises a cell.
  • the method comprises measuring light emission, wherein detection of light emission indicates that the biomolecule has been processed by a lysosome.
  • kits comprising a compound of Formula I or III, and a biomolecule.
  • the kit comprises a conjugate of Formula II or IV.
  • FIG. 1A illustrates Probe/ Assay design.
  • FIG. IB describes a mechanism whereby conjugates of the present disclosure allow monitoring of internalization of biomolecules of interest.
  • FIG. 2 illustrates a dose dependent bioluminescence from thioluciferin and thioluciferin- labeled octa-arginine peptide (r8-SS-luc).
  • FIG. 3 shows a general principle of the antibody uptake assay design.
  • FIG. 4A shows bioluminescent signal from a cellular uptake of Trastuzumab-thioluciferin (Trastuzumab-SS-Luc) and IgG-thioluciferin (IgG-SS-Luc) antibodies in Her2 positive SK-BR-3 luciferase expressing cell lines at different time points.
  • FIG. 4B shows the bioluminescent signal from Trastuzumab-thioluciferin normalized to that from IgG-thioluciferin at each time points over the course of 48 hrs.
  • FIG. 5A shows bioluminescent signal from a cellular uptake of Trastuzumab- thioluciferin and IgG-thioluciferin antibodies in Her2 negative 4T1 luciferase expressing cell lines over the course of 48 hrs.
  • FIG. 5B shows the bioluminescent signal from Trastuzumab-thioluciferin normalized to that from IgG- thioluciferin at each time points.
  • FIGS. 6A-6D shows comparison of Trastuzumab-thioluciferin uptake normalized to IgG- thioluciferin uptake in two Her2 positive (SK-BR-3 and BT474 in FIG. 6A and FIG. 6B, respectively) and two Her2 negative luciferase expressing cell lines (4T1 and MDA-MB231 in FIG. 6C and FIG. 6D, respectively).
  • FIG. 7 provides data of cold antibody competition assay with Trastuzumab-thioluciferin and Trastuzumab along in BT474 Her2 positive cell line.
  • FIG. 8 provides signal from in vivo uptake of Trasuzumab-thioluciferin and control IgG- thioluciferin in BT474-Luc tumor xenograft mouse model.
  • FIGS. 9A-9B illustrate data from bioluminescence from 4T1 RLR transfected with DNA- SS-luc (DNA-thioluciferin) using lipofectamine (FIG. 9A) and polyethyleneimine (FIG. 9B) transfection reagents.
  • polypeptide includes a single polypeptide as well as two or more of the same or different polypeptides
  • agent includes a single agent as well as two or more of the same or different agents, and the like.
  • Luciferase refers to an enzyme that oxidizes a corresponding luciferin, thereby causing bioluminescence. Luciferase enzymes can be found in bacteria, fireflies, fish, squid, dinoflagellates, and other organisms capable of bioluminescence. Luciferase, as used herein, can include prokaryotic and eukaryotic luciferases, as well as variants possessing varied or altered optical properties.
  • Luciferin refers to a substrate for a luciferase enzyme. Luciferins typically undergo an enzyme-catalyzed oxidation and the resulting excited state intermediate emits light (photons) upon decaying to its ground state.
  • Luciferin as used herein can refer to any one or more of the following non-exhaustive list: a luciferin derivative or analog, a preluciferin or analog, coelenterazine or a coelenterazine derivative or analog, pro-luciferin, aminoluciferin, quionolyl- luciferin, napthyl luciferin, chloroluciferin, coelenterazine, furimazine, coelenterazine-n, coelenterazine-f, coelenterazine -h, coelenterazine-hcp, coelenterazine-cp, coelenterazine-c, coelenterazine-c, coelenterazine-e, coelenterazine-fcp, bis-deoxycoelenterazine ("coelenterazine-hh"), coelenterazine-i, coelenterazine-icp, coelenterazine-v, and 2-methyl coelent
  • alkyl as used herein is intended to include a monovalent branched and straight- chain saturated aliphatic hydrocarbon groups having one to twenty number of carbon atoms.
  • Ci-Cio as in “Ci-Cio alkyl” is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement.
  • Ci-Cio alkyl specifically includes methyl, ethyl, n- propyl, i-propyl, n-butyl, t-butyl, i-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on.
  • alkylene as used herein is intended to include a bivalent, branched or straight- chain saturated aliphatic hydrocarbon groups having one to twenty number of carbon atoms.
  • Ci-io as in "Ci-io alkylene” is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement.
  • C1-3 alkylene includes methylene, ethylene, and propylene (-CH2CH2CH2- or -CFECHiOFE)-).
  • alkoxy refers to -O-alkyl wherein alkyl is defined as above.
  • cycloalkyl means a monovalent monocyclic, bicyclic or spirocyclic saturated aliphatic hydrocarbon group having three to twenty number of carbon atoms.
  • the cycloalkyl can be bridged (i.e., forming a bicyclic moiety), for example with a methylene, ethylene or propylene bridge.
  • the cycloalkyl may be fused with an aryl group such as phenyl, and it is understood that the cycloalkyl substituent is attached via the cycloalkyl group.
  • cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so on.
  • cycloalkylene means a bivalent monocyclic, bicyclic or spirocyclic saturated aliphatic hydrocarbon group having three to twenty number of carbon atoms.
  • the ring structure of cycloalkylene is the same as that of cycloalkyl.
  • Aryl is intended to mean any stable monovalent monocyclic, bicyclic or tricyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic.
  • the aryl can have six to twenty carbon atoms. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl and biphenyl. In cases where the aryl substituent is bicyclic or tricyclic and one ring is non aromatic, it is understood that attachment is via the aromatic ring.
  • aryl is an aromatic ring of 6 to 14 carbon atoms, and includes a carbocyclic aromatic group fused with a 5- or 6-membered cycloalkyl group such as indan.
  • carbocyclic aromatic groups include, but are not limited to, phenyl, naphthyl, e.g. 1-naphthyl and 2-naphthyl; anthracenyl, e.g. 1-anthracenyl, 2-anthracenyl; phenanthrenyl; fluorenonyl, e.g. 9- fluorenonyl, indanyl and the like.
  • Arylene is intended to mean any stable bivalent monocyclic, bicyclic or tricyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic.
  • the bovalent attachment point can be on a saturated or unsaturated carbon.
  • the ring structure of arylene is the same as that of aryl.
  • heteroaryl represents a stable monovalent monocyclic, bicyclic or tricyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains carbon and from 1 to 4 heteroatoms selected from the group consisting of O, N and S.
  • heteroaryl refers to a monocyclic, bicyclic or tricyclic aromatic ring of 5- to
  • heteroaryl 14-ring atoms of carbon and from one to four heteroatoms selected from O, N, or S.
  • heteroaryl is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
  • the attachment is via the heteroatom containing aromatic ring, respectively.
  • optionally substituted refers to the moiety following “optionally substituted” (such as alkyl) is not substituted or substituted.
  • the moiety can be substituted with one, two, or three groups independently selected from alkyl, alkoxy, halogen, CN, cycloalkyl, aryl and heteroaryl.
  • immunoglobulin refers to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) low molecular weight chains and one pair of heavy (H) chains, all four inter-connected by disulfide bonds.
  • L light
  • H heavy
  • each heavy chain typically is comprised of a heavy chain variable region (abbreviated herein as VH or VH) and a heavy chain constant region.
  • VH or VH heavy chain variable region
  • the heavy chain constant region typically is comprised of three domains, CHI, CH2, and CH3.
  • Each light chain typically is comprised of a light chain variable region (abbreviated herein as VL or VL) and a light chain constant region.
  • the light chain constant region typically is comprised of one domain, CL.
  • the VH and VL regions may be further subdivided into regions of hypervariability (or hypervariable regions which may be hypervariable in sequence and/or form of structurally defined loops), also termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the numbering of amino acid residues in this region is performed by the method described in Rabat et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
  • the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain.
  • a heavy chain variable domain may include a single amino acid insert (residue 52a according to Rabat) after residue 52 of V.sub.H CDR2 and inserted residues (for instance residues 82a, 82b, and 82c, etc. according to Rabat) after heavy chain FR residue 82.
  • the Rabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Rabat numbered sequence.
  • antibody in the context of the present invention refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically bind to an antigen under typical physiological conditions with a half-life of significant periods of time, such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally-defined period (such as a time sufficient to induce, promote, enhance, and/or modulate a physiological response associated with antibody binding to the antigen and/or time sufficient for the antibody to recruit an Fc-mediated effector activity).
  • significant periods of time such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours
  • variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system such as Clq, the first component in the classical pathway of complement activation.
  • the term antibody herein unless otherwise stated or clearly contradicted by context, includes fragments of an antibody that comprise a mutated or wildtype core hinge region and retain the ability to specifically bind to the antigen. [0062] It has been shown that the antigen-binding function of an antibody may be performed by fragments of a full-length antibody.
  • binding fragments encompassed within the term "antibody” include, e.g. F(ab')2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region. Although such fragments are generally included within the meaning of antibody, they collectively and each independently are unique features of the present invention, exhibiting different biological properties and utility.
  • antibody also includes polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, such as chimeric antibodies and humanized antibodies, and antibody fragments retaining the ability to specifically bind to the antigen (antigen-binding fragments) provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.
  • mAbs monoclonal antibodies
  • antibody-like polypeptides such as chimeric antibodies and humanized antibodies
  • antibody fragments retaining the ability to specifically bind to the antigen (antigen-binding fragments) provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.
  • An antibody as generated can possess any isotype.
  • the terms "monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • the term “human monoclonal antibody” refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences.
  • the human monoclonal antibodies may be generated by a hybridoma which includes a B cell obtained from a transgenic or transchromosomal nonhuman animal, such as a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene, fused to an immortalized cell.
  • binding in the context of the binding of an antibody to a predetermined antigen typically is a binding with an affinity corresponding to a KD of about 10 7 M or less, such as about 10 8 M or less, such as about 10-9 M or less, about 10 10 M or less, or about
  • a KD surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using the antigen as the ligand and the antibody as the analyte, and binds to the predetermined antigen with an affinity corresponding to a KD that is at least ten-fold lower, such as at least 100 fold lower, for instance at least 1000 fold lower, such as at least 10,000 fold lower, for instance at least 100,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely -related antigen.
  • a non-specific antigen e.g., BSA, casein
  • the amount with which the affinity is lower is dependent on the KD of the antibody, so that when the KD of the antibody is very low (that is, the antibody is highly specific), then the amount with which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 10,000 fold.
  • kd (sec 1 ), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. Said value is also referred to as the k 0ff value.
  • k a (M l x sec 1 ), as used herein, refers to the association rate constant of a particular antibody-antigen interaction.
  • KD (M) refers to the dissociation equilibrium constant of a particular antibody-antigen interaction.
  • KA (M 1 ), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction and is obtained by dividing the k a by the k d .
  • therapeutic polypeptide refers to a polypeptide which provides therapeutic efficacy when administered to a subject suffering from a disease or disorder.
  • a therapeutic polypeptide includes but is not limited to a therapeutic antibody, fragment or derivative thereof.
  • reducing agent refers to a compound which reduces molecules in its environment, i.e., which changes molecules in its environment to become more reduced and more reducing.
  • a reducing agent acts by donating electrons, thereby becoming itself oxidized after having reduced a substrate.
  • a reducing agent is an agent which donates electrons.
  • reducing agents include but are not limited to dithiothreitol (DTT), mercaptoethanol, cysteine, thioglycolate, cysteamine, glutathione, and sodium borohydride.
  • the reducing agent does not comprise an enzyme.
  • ADCs Antibody Drug Conjugates bind to an extracellular domain of their target receptor, leading to receptor internalization via endocytosis followed by lysosomal degradation of the Ab- receptor complex and cytosolic release of the toxin. Success of an ADC is closely correlated with endosomal sorting and lysosomal degradation kinetics of the antibody-receptor complex.
  • the cargo e.g. drug conjugate
  • the existing methodologies rely on imaging fluorophore- or radio-labelled antibodies using invasive techniques, which do not directly reveal cytosolic delivery of the cargo and are not in real-time.
  • BL-ICU Bioluminescence Imaging of Cellular Uptake
  • the assay is based on the well-characterized chemical energetic transition that occurs when the Firefly luciferase enzyme catalyzes the oxidation of D-luciferin to oxyluciferin.
  • the resulting electronically excited state emits a yellow-green photon which can be detected via photomultiplier instruments.
  • bioluminescence is a highly sensitive imaging modality due to the extremely low auto-luminescence present in mammalian cells and tissues, and it can easily be adapted to high- throughput screening systems.
  • FIG. 3 The overall BL-ICUP in vitro assay principle is summarized in FIG. 3.
  • Relevant target cells pre-engineered to constitutively express Firefly luciferase in the cytosol
  • an antibody conjugated with luciferin Ab-SS-Luciferin
  • luciferin Ab-SS-Luciferin
  • a bound surface complex is formed. This complex can either reversibly dissociate, remain largely at the cell surface, or become internalised into the endosomal vesicular network. In the latter scenario, early endosomal vesicles can either recycle the bound complex back to the cell surface or direct the contents for lysosomal degradation.
  • examples of the present disclosure are directed to an antibody conjugate comprising an antibody or fragment thereof conjugated to a thioluciferin derivative
  • the luciferin compounds or moieties described herein, e.g., Formulae I or III can be conjugated to a biomolecule such as polypeptide or protein to form a conjugate of Formula II or IV.
  • a polypeptide according to the present disclosure alternatively referred to herein as a protein, can be a monomeric, dimeric or multimeric protein.
  • the luciferin compounds or moieties described herein, e.g., Formulae I or III can be conjugated to other biomolecules, such as molecules with a specific binding activity.
  • biomolecules can further include small molecules, nucleotides, oligonucleotides and siRNA. It can also be conjugated to therapeutic viral particles.
  • L is a bioluminescent reporter or a pro-luminescent moiety
  • X is an alkylene
  • Z is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted
  • the optionally substituted alkyl is an alkyl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • the optionally substituted alkylene is an alkylene optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • the optionally substituted alkylene is a C1-C7 alkylene, such as Ci, C2, C3, C4, C5, Ce, or C7 alkylene, optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • the optionally substituted alkylene is a unsubstituted C1-C7 alkylene, such as unsubstituted Ci, C2, C3, C4, C5, Ce, or C7 alkylene.
  • the optionally substituted aryl is an aryl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • the optionally substituted arylene is an arylene optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • the optionally substituted cycloalkylene is a cycloalkene optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is wherein Y is C1-C6 alkylene and A is as defined above.
  • L _g _ 1 L -U _ I is 1 wherein Y is C1-C6 alkylene some embodiments, Z is * wherein Y is C2 or Ce alkylene and A is as defined above. In some embodiments, Z is wherein
  • Y is C2 or Ce alkylene
  • Z is an aryl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is an unsubstituted aryl such as phenyl.
  • Z is a heteroaryl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is an unsubstituted heteroaryl such as pyridine.
  • Z is an alkyl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is C1-C4 alkyl optionally substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is a methyl substituted with one, two, or three groups selected from alkyl, alkoxy, CN, halogen, aryl, cycloalkyl, and heteroaryl.
  • Z is a methyl substituted with three aryl groups such as phenyl groups.
  • X is a Ci-Ce alkylene. In some embodiments, X is a C1-C4 alkylene. In some embodiments, X is C2, C3 or C4 alkylene.
  • L is a luciferin, a luciferin derivative or analog, a preluciferin or analog, coelenterazine or a coelenterazine derivative or analog thereof.
  • L is selected from the group consisting of aminoluciferin, quionolyl-luciferin, napthyl luciferin, chloroluciferin, fluoroluciferin, coelenterazine, furimazine, coelenterazine-n, coelenterazine-f, coelenterazine-h, coelenterazine-hcp, coelenterazine-cp, coelenterazine-c, coelenterazine-c, coelenterazine-e, coelenterazine-fcp, bis-deoxy coelenterazine ("coelenterazine-hh"), coelenterazine-i, coelenterazine- icp, coelenterazine-v, and 2-methyl coelenterazine
  • a compound of Formula I is a compound of Formula III or a salt thereof , and X are the same as defined for Formula I including each embodiments thereof.
  • a compound of Formula III is a compound selected from yanobenzothiazoles) [0091] Also provided is a compound of Formula V or a salt thereof:
  • L is a luciferin, a luciferin derivative or analog, a preluciferin or analog, coelenterazine or a coelenterazine derivative or analog thereof.
  • L is selected from the group consisting of aminoluciferin, quionolyl-luciferin, napthyl luciferin, chloroluciferin, fluoroluciferin, coelenterazine, furimazine, coelenterazine-n, coelenterazine-f, coelenterazine-h, coelenterazine-hcp, coelenterazine-cp, coelenterazine-c, coelenterazine-c, coelenterazine-e, coelenterazine-fcp, bis-deoxy coelenterazine ("coelenterazine-hh"), coelenterazine-i, coelenterazine-icp, coelenterazine-v, and 2-methyl coelenterazine
  • X is a Ci-Ce alkylene. In some embodiments, X is a C1-C4 alkylene. In some embodiments, X is C2, C3 or C4 alkylene.
  • a compound of Formula V is a compound of Formula VI or a salt thereof: r -CN, and X is as defined in Formula V including each embodiment thereof.
  • the compound of Formula VI is in the application, the moiety of this compound without H attached to the sulfur is referred to -S-Luc. This compound or the moiety of this compound without H attached to the sulfur is also termed thioluciferin.
  • the compound described above can be conjugated to any polypeptide (protein) or derivative thereof that comprises a free amine.
  • the free amine containing protein can be directly incubated in the presence of a composition comprising a compound of Formula I or III.
  • the compound incubated with a free amine containing (lysine, arginine, or N-terminus) protein is AT-Luc or AT-CBT.
  • the protein is an antibody or fragment thereof.
  • the compound described above can be conjugated to any polypeptide (protein) or derivative thereof that comprises a sulfur group such as the -SH group of a cysteine residue, wherein the sulfur group can form a disulfide bond.
  • the sulfur- containing residue can be present in a disulfide bond within the native polypeptide.
  • the disulfide bond can be intramolecular (between two residues on a single polypeptide) or inter molecular (between two residues, wherein each residue is on a separate polypeptide in a dimeric or multimeric protein).
  • Conjugating a compound with a protein containing a disulfide bond can be achieved by first partial disulfide bond reduction, wherein no more than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80% of the disulfide bonds in the protein on average are reduced.
  • the partially reduced protein is then incubated in the presence of a composition comprising a compound of Formula I or III.
  • the compound incubated with the partially reduced protein is TT-Luc.
  • the protein is an antibody or fragment thereof.
  • the polypeptide of interest is site specifically engineered to include a free Cysteine, Lysine or Arginine residue, which could be directly conjugated to the imaging reagent without reducing the disulfide bonds.
  • the compound of Formula III is conjugated to free amino groups or cysteine residues of an antibody or fragment or derivative thereof via amide or disulfide bond to form a conjugate referred to herein as “Ab-SS -Luciferin”.
  • the compound of Formula I or III may also be conjugated to a peptide, such as a peptide having a length ranging from 10-20, 15-30, 20-40, 10 to 50 or 25 to 50 amino acids in length, wherein the peptide comprises 1-5, 1-4, 1-3, 1-2, 1, 2, 3, 4 or 5 cysteines.
  • a peptide such as a peptide having a length ranging from 10-20, 15-30, 20-40, 10 to 50 or 25 to 50 amino acids in length, wherein the peptide comprises 1-5, 1-4, 1-3, 1-2, 1, 2, 3, 4 or 5 cysteines.
  • Such peptides can be treated to allow disulfide bond formation between two peptides, then the disulfide-bonded peptides are incubated under reducing conditions to conjugate a TT-Luc compound to one or both peptides.
  • the compound of Formula I or III may also be conjugated to a peptide, such as a peptide having a length ranging from 2-8, 5-15, 10-20, 15-30, 20-40, 10 to 50 or 25 to 50 amino acids in length.
  • a peptide such as a peptide having a length ranging from 2-8, 5-15, 10-20, 15-30, 20-40, 10 to 50 or 25 to 50 amino acids in length.
  • the luciferin derivative such TT-luc and AT-luc can be conjugates to any small molecule drugs, metabolites (ex. lipids), vitamins, nanoparticles, and viruses using the same strategy described for peptides and antibodies above.
  • B comprises a biomolecule
  • X and L are the same as defined for Formula I including each embodiment thereof.
  • the biomolecule is a protein, peptide or derivatives as described above.
  • the biomolecule is a polypeptide or peptide.
  • the biomolecule is a protein containing viral particle.
  • the polypeptide is an antibody or fragment or derivative thereof.
  • the antibody or fragment or derivative thereof is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, an F(ab)2, a diabody or a probody.
  • the antibody is a bispecific antibody, a multispecific antibody, an scFv, a F(ab)2, a bis-scFv, a diabody, a triabody or a tetrabody.
  • the antibody or fragment or derivative thereof is therapeutic.
  • the biomolecule is a nucleotide or an oligonucleotide.
  • the biomolecule is siRNA, shRNA or any other silencing RNA molecule.
  • the polypeptide is an antibody, fragment or derivative thereof which specifically binds an antigen, wherein the binding activity of the conjugate is not reduced by more than 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60% or 75% as compared to the binding activity of the antibody, fragment or derivative thereof which is not conjugated.
  • the polypeptide is an antibody or fragment or derivative thereof comprising a disulfide bond, wherein no more than 10%, 20%, 30%, 40%, 50% or 60% of the disulfide bonds in the polypeptide are reduced for the formation of the conjugate.
  • the biomolecules are selected from, for example, small molecule drugs, sugars, vitamin, peptides (oligo or poly), lipids, necleotides, oligosaccharides, anitbodies, antibody drug conjugates, DNA, siRNA, RNA, nanoparticles, and virus.
  • the biomolecules comprise, for example, an amino, hydroxyl, or thiol group.
  • a conjugate of Formula II is a conjugate of Formula IV or a salt thereof: or-CN, B comprises a biomolecule, and X is the same as defined for
  • the method can comprise incubating a conjugate of Formula II or IV with an enzyme such as luciferase wherein the enzyme such as luciferase can act on the bioluminescent such as luciferin moiety of Formula II or IV after the disulfide bond of Formula II or IV is cleaved to generate light.
  • an enzyme such as luciferase
  • the enzyme such as luciferase can act on the bioluminescent such as luciferin moiety of Formula II or IV after the disulfide bond of Formula II or IV is cleaved to generate light.
  • the luciferase is expressed by a cell which is contacted with the conjugate for a period of time, e.g., 1-10 min, 10 to 20 min, 10-30 min, 15 to 60 min, 1-2 h, 1-5 h, 1-10 h, 1-20 h, or 1-30 h.
  • the luciferase expressed by the cell can be an endogenous, naturally occurring luciferase or a recombinant luciferase wherein the cell was engineered to express the luciferase.
  • W in Formula IV is -CN
  • the “full”-luciferin moiety capable of bioluminescent light emission e.g., the moiety comprising
  • W in Formula IV is -CN
  • the “full”-luciferin moiety capable of bioluminescent light emission e.g., the moiety comprising
  • This “split luciferin” approached is illustrated in the scheme below:
  • a biomolecule of interest such as a protein
  • CBT cyanobenzothiazole
  • This can be converted into corresponding luciferin conjugate (protein-SS-Luc) by addition of D-cysteine or the protein-SS-CBT can be used directly to probe cell uptake process to form active luciferin upon reaction with intracellular D-cysteine.
  • This approach similarly does limit the biomolecules to proteins. Neither does this approach limit the compound of Formula IV to AT-CBT and TT-CBT.
  • the biomolecules disclosed for Formula II or IV and the compounds of Formula IV when W is CN are all suitable for this approach.
  • Cells for use in the methods can be eukaryotic or prokaryotic.
  • Eukaryotic cells include but are not limited to yeast, avian, plant, insect and mammalian cells.
  • the conjugate is incubated with a cell which does not express endogenous or recombinant luciferase.
  • the cell and conjugate are incubated with a composition comprising the luciferase.
  • the method comprises incubating a luciferase-expressing cell with a conjugate of Formula IV wherein B is an antibody.
  • B is an antibody.
  • an effective antibody that binds to a receptor or protein on the surface of the cell will be endocytosed by the cell.
  • the Ab-SS-Luciferin is shuttled to the lysosome, it is degraded to yield luciferin fragments with the disulfide bond. Then, these fragments are delivered into the reducing cytosolic environment where the disulfide bond is cleaved, releasing the luciferin.
  • Luciferase expressed by the cell is then able to use the free luciferin as a substrate, thereby generating light.
  • the antibody (Ab) in this embodiment can be a fragment or derivative of an antibody as described herein or may be any protein or polypeptide which can bind to a receptor or protein on the surface of the cell.
  • FIG.1A describes examples of conjugates of Formula IV.
  • the biomolecule comprises a free amino or thiol group.
  • the biomolecules can be small molecule drugs, sugars, vitamin, peptides, lipids, nucleotides, oligosaccharides, antibodies, antibody drug conjugates, DNA, siRNA, RNA, nanoparticles, and virus.
  • the biomolecule of interest bearing free amino or thiol group or modified with linker bearing such groups can be tagged with Amino Tag Luciferin (AT-Luc) or Thiol Tag Luciferin (TT-Luc) respectively to afford a SS-Luc tagged biomolecule.
  • AT-Luc Amino Tag Luciferin
  • TT-Luc Thiol Tag Luciferin
  • FIG. IB uses an exemplary conjugate, i.e., a SS-Luc tagged biomolecule, illustrating the uptake probe mechanism: SS-Luc tagged molecule is taken up by a luciferase-expressing cell; upon internalization, the probe is reduced by ubiquitous glutathione liberating reporter molecule mercaptopropylaminoluciferin capable of enzymatic oxidation with firefly luciferase emitting light. Amount of detected light is proportional to intensity of cellular uptake of the probe.
  • Example 1 describes synthetic schemes and procedures for compounds AT-Luc and TT-Luc (precursors for thioluciferin labeling).
  • Examples 2, 4, 6, 7, 8, and 9 describe labeling procedures for various biological molecules with thioluciferin either with AT-Luc or TT-Luc molecules, including labeling of peptides, antibodies, small molecules such as a free fatty acids and triglycerides, and DNA.
  • Examples 3, 5, and 10 below describes cell uptake of peptide or antibody labeled with thioluciferin or transfection with DNA labeled with thioluciferin.
  • Example 3 The study in Example 3 is a dose dependent uptake study of a peptide conjugate D- Octaarginine-thioluciferin (abbreviated as r8-SS-Luc or 8-SS-Luc) in cells.
  • the conjugate r8-SS- Luc was prepared according to Example 2.
  • FIG. 2 displays integrated luminescence over 3 h from cells incubated with r8-SS-luc in HBSS and 25 mM glucose.
  • FIG. 3 shows general antibody-thioluciferin uptake assay design.
  • the thioluciferin labeled antibody undergoes endocytosis with subsequent release of thioluciferin molecule.
  • the light is emitted proportionally to the amount of endocytosed antibody.
  • Example 5 shows the successful use of the antibody conjugates of Formula II or IV to monitor cellular uptake and processing of a protein upon binding to a cell surface receptor both in vitro and in vivo.
  • a protein conjugate (trastuzumab-thioluciferin antibody conjugate, also abbreviated as Trastuzumab-SS-luc, prepare according to Example 4) which binds specifically to a receptor (Her2) on the cell shows increasing luminescence over time, demonstrating the uptake and processing of the conjugate by the cells to release the luciferin moiety from the conjugate.
  • a control conjugate (IgG antibody -thioluciferin conjugate, also abbreviated as IgG-SS-luc prepared according to Example 4) which did not contain a protein which internalizes inside the cells resulted in the production of only background signal.
  • an increase in luminescence was observed only when the conjugate contains a protein which binds specifically to the cell surface receptor and gets internalized and processed via lysosome in the subsequent step of the assay. If no internalization occurs upon binding to the receptor, no light is produced from the conjugates of interest. That makes the assay very specific for sensitive monitoring of internalization of biomolecules inside the cells. The process can be extended to monitoring of intracellular internalization in live cells and living animals.
  • FIGS. 4A-4B show uptake of trastuzumab-thioluciferin and IgG-thioluciferin antibodies in Her2 positive SK-BR-3 luciferase expressing cell lines as a function of time.
  • FIG. 4A shows the bioluminescent signal measured at different time points for the positive cells incubated with trastuzumab-thioluciferin and IgG-thioluciferin antibodies.
  • FIG. 4B is a chart showing signal from Trastuzumab-thioluciferin normalized to the negative IgG-thioluciferin control signal at each time point. The peak ratio of over 40 folds was achieved at 24hrs time point.
  • Example 5 also treated Her2 negative 4T1 luciferase expressing cell lines with incubated trastuzumab-thioluciferin and IgG-thioluciferin antibodies. No increase of the signal from the Trastuzumab treated cells was observed.
  • FIG. 5A shows bioluminescent signal measured at different time points for the negative cells incubated with trastuzumab-thioluciferin and IgG- thioluciferin antibodies.
  • FIG. 5B is a chart showing signal from Trastuzumab-thioluciferin normalized to the negative IgG-thioluciferin control signal at each time point. The ratio of Trastuzumab signal over the IgG signal remained close to 1 in this experiment.
  • FIGS. 6A-6D show high normalized signal ratios of Trastuzumab-thioluciferin over IgG-thioluciferin for Her 2 positive cells (FIG. 6A and FIG. 6B) and low normalized signal ratios for Her 2 negative cells (FIG. 6C and FIG. 6D).
  • Example 5 further conducted a competition assay.
  • BT474 Her 2 positive cells were incubated with either 2ng of trastuzumab-thioluciferin antibody alone or with 2 ng trastuzumab-thioluciferin plus high amounts of cold unlabeled trastuzumab antibody (lOng or lOOng).
  • FIG. 7 shows signals from the cells treated with labeled antibody plus non labelled cold antibody was dramatically lower than the signal obtained with labeled antibody alone, further validating the specificity of the assay.
  • Example 5 additionally conducted an in vivo study on the uptake of Trasuzumab- thioluciferin and control IgG-thioluciferin in BT474-Luc tumor xenograft mouse model.
  • Mice were injected with equal amounts of either Trastuzumab-thioluciferin or IgG-thioluciferin and imaged at different time points using IVIS Spectrum instrument.
  • FIG. 8 displays normalized photon flux for Trastuzumab-thioluciferin and IgG-thioluciferin at different time points.
  • the kinetics and strength of the signal from trastuzumab injected animals was significantly higher than the signal from the IgG injected animals, suggesting that the BL-ICUP signal can be used in vivo as well.
  • the cellular uptake assay described herein can also be used to assess the activity of extracellular enzyme (such as lipase) in situations where internalization of a conjugate occurs after the biomolecule moiety of the conjugate is modified by an extracellular enzyme wherein the conjugate/biomolecule is a substrate or potential substrate to the enzyme.
  • extracellular enzyme such as lipase
  • Example 8 demonstrates applications of thioluciferin as a bioluminescent reporter in enzymatic and cell-based internalization assays simultaneously. Only in case if both are present/active the light production will occur.
  • Example 8 specifically demonstrates that only if the lipase is active and fatty acid is cleaved from triglyceride backbone as the result of lipase activity, the cellular internalization of thioluciferin-labeled fatty acid can occur. That would result in light production that can be imaged and quantified by the bioluminescence assay disclosed herein.
  • the biomolecule (Triglyceride-SS-Luc) is a substrate for lipase, after cleavage a part of the conjugate (palmitic acid - SS- Luc) is internalized and quantified by BL-ICU assay.
  • Example 10 reports a transfection study with a DNA-thioluciferin (also abbreviated DNA- SS-Luc), which was prepared according to Example 9.
  • DNA-SS-Luc DNA-thioluciferin plus lipofectamine or polyethylene imine at different concentration were incubated with cells for a period of time.
  • the bioluminescence was measured in the IVIS spectrometer, and the results were shown in FIG. 9A and FIG. 9B.
  • FIG. 9A shows bioluminescence from 4T1 RLR cells after 6 h incubation with bpofectamine (TA) and DNA-SS-luc, wherein +++TA corresponds to 0.6 pi/ 96 well, ++TA to 0.3 m ⁇ / 96 well, +TA to 0.15 m ⁇ / 96 well.
  • TA bpofectamine
  • FIG. 9B shows integrated bioluminescence from 4T1 RLR cells during 80 min incubation with polyethyleneimine (TA) and DNA-SS-luc, wherein +++TA corresponds to 1.0 pg/ 96 well, +TA to 0.25 pg/ 96 well.
  • TA polyethyleneimine
  • the flexible nature of the BL-ICU assay can allow sensitive and real-time screening of cellular internalization of a number of biomolecules such as small molecule drugs, vitamins, metabolites (lipids, glucose, etc.), peptides, antibodies, antibody drug conjugates, proteins, nanoparticles, viruses, cells, and bacteria in the same assay as well as in various cell lines including suspension cells.
  • biomolecules such as small molecule drugs, vitamins, metabolites (lipids, glucose, etc.), peptides, antibodies, antibody drug conjugates, proteins, nanoparticles, viruses, cells, and bacteria in the same assay as well as in various cell lines including suspension cells.
  • the assay developed here does not involve any invasive steps, which will readily allow longitudinal imaging both in vitro and in vivo. Additionally, knowing the real-time kinetics of the molecule uptake in a target organ can be highly valuable for dose treatment and pharmacokinetic (PK) studies, therefore, this approach could be useful for many biomolecules including therapeutic antibody development and biomedical applications.
  • PK pharmacokinetic
  • BL-ICUP assay can directly be translated to in vivo applications. In addition to real-time uptake in the target organ, cellular internalization of the antibody in healthy tissues could be detected, which would give prior information about the potential side effects.
  • the in vivo imaging techniques available for biomolecules give information mainly about the tissue distribution of the biomolecules rather than cellular internalization kinetics in vivo. For example, they do not allow monitoring in real time degradation of antibodies and cytosolic release of the drug cargo from ADC.
  • this BL-ICU assay is not limited to the biomolecules provided in the examples and could readily be extended to other proteins, peptides, small molecules, viruses, nanoparticles and oligonucleotides such as siRNA to monitor cellular uptake both in vitro and in vivo.
  • Reaction conditions i) TEA, CH2CI2, room temperature, overnight; ii) NaBH(OAc)3, AcOH, THF, room temperature, overnight; iii) THF/water (2:1), room temperature, 1 h; iv) hydrazine monohydrate, N2, 0°C to room temperature, 30 min; v) TEA, DMF, N2, room temperature, 2 h.
  • 4T1-RLR cells were plated in 96 well plates in DMEM medium supplemented with FBS
  • FIG. 2 is a chart showing luminescence at different doses of 8 (A) and 13 (B).
  • IgG-SS-Luc 0.77 mg/mL (protein concentration) and 4.11 (degree of labeling).
  • luciferase expressing cells were seeded in 24 well plates at approximately 50% confluency. Thioluciferin labeled antibody (2 ng) were then added directly into the cell culture media, the cells were incubated with antibody for different time intervals and the bioluminescent signal was acquired using IVIS imaging instrument (Perkin Elmer). Fig. 4A and FIG.
  • FIG. 4B show the results of the experiment where SK-BR-3 Her2 positive cells were incubated with either thioluciferin labeled trastuzumab antibody (trastuzumab-SS-Luc or Trastuzumab-thioluciferin) which specifically binds Her2 receptor and efficiently internalizes inside the cells, or with nonspecific thioluciferin labeled IgG antibody (IgG-SS-Luc) which does not bind any cell surface antigens.
  • the signal from Trastuzumab-SS-Luc treated cells significantly increases during the first 48 hours of incubation, while the signal from negative control IgG-SS-Luc antibody remains at the background level for the duration of experiment.
  • Fig 4B shows the ratio of trastuzumab- thioluciferin signal over the control IgG signal at different time points.
  • FIG. 6A-D which summarize the results with high ratios of Trastuzumab-thioluciferin over IgG for Her2 positive cell lines, and low ratios for Her2 negative cell lines.
  • BT474 Her 2 positive cells were incubated either with 2ng of trastuzumab-thioluciferin antibody alone, or with 2 ng of trastuzumab- thioluciferin plus high amounts of cold unlabeled trastuzumab antibody (lOng, lOOng, competition assay).
  • the signal from the cells treated with labeled antibody plus non-labelled cold antibody was dramatically lower than the signal obtained with labeled antibody alone, further validating the specificity of the assay. See FIG. 7.
  • the antibody uptake assay was investigated in vivo in subcutaneous xenograft tumors.
  • 5M luciferase labeled BT474 cells were injected subcutaneously into the right flank of nude mice. The tumors were allowed to grow until approximately 0.5 cm3 in size. The mice were then injected with 50ng of trastuzumab-thioluciferin or IgG-thioluciferin antibodies, respectively.
  • the bioluminescent signal was acquired at different time intervals using IVIS Spectrum imaging instrument (Perkin Elmer). See FIG. 8. The kinetics and strength of the signal from trastuzumab injected animals was significantly higher than the signal from the IgG injected animals, suggesting that the BL-ICUP assay can be used in vivo as well.
  • Reaction conditions i) TT-Luc, DIPEA, THF-DMF, RT, 12 h.
  • Thioluciferin (SS-Luc) labelled glycerol tripalmitate molecule was designed for measuring of lipase enzyme activity. Prior to labeling with TT-Luc agent, a terminal thiol group was introduced to the structure triglyceride molecule according to next synthetic scheme
  • Reaction conditions i) 2,2'-dithiopyridine, DIPEA, THF, rt, 3h; ii) EDCI, DMAP, DCM, 0°C to RT, 16 h; iii) 8, DIPEA, DCM, rt, 16 h.
  • 16-(pyridin-2-yldisulfaneyl)hexadecanoic acid A mixture of 16- mercaptohexadecanoic acid 16 (289 mg, 1.0 mmol), 2,2'-dithiopyridine (231 mg, 1.05 mmol), and THF (6 mL) stirred at RT for 3 h under nitrogen atmosphere. Then the reaction mixture was diluted with DCM (20 mL), washed with water (3x20 mL), dried over Na2S04, and evaporated to dryness to give 17 as a yellowish solid (near quantitative yield).
  • the nanodrop dilution series indicated 0.260 mg in this fraction which was much more than the expected amount.
  • 9.7 m ⁇ (97 pg, 210 nmol, 6 eq.) of TT-Luc solution in DMF is added to the DNA in buffer and the mixture was stirred at room temperature for 4 h.
  • the solution was concentrated with viva spin columns and transferred to 2 mL Eppendorf tubes. NaOAc was added (to 0.3 M end concentration) and pure EtOH (to 75 % end concentration).
  • the solution was cooled to -80 °C over night (30 min are usually sufficient) and centrifuged at 4 °C and 10000 g for 20 min.
  • lxlO 4 cells per well in RPMI were plated in 96 well plates and incubated for two days.
  • a 40 mM solution of DNA was prepared by measuring the concentration on Nanodrop with an absorption coefficient of 289282 L/(cm*mol) at 650 nm.
  • the absorption coefficient of the DNA strand is 220000 L/(cm*mol) at 260 nm, but less exact.
  • 4T1RLR cells were seeded in RPMI medium with 10 4 cells/96 well two days before the experiment.
  • the medium was removed and the cells were washed three times with 100 pL optimem medium.
  • the transfecting mixtures in medium are added. Different concentrations of DNA, and transfecting agent were used.
  • +TA means 0.15 pl/well
  • ++TA means 0.3 pl/well.
  • +++TA means 0.6 pl/well for lipofectamine transfection and +TA means 0.12 pg/well, ++TA means 0.25 pg/well, +++TA means 0.5 pg/well polyethylene imine.
  • the linear polyethylene imine had an average molecular weight of 13 kDa and a maximum molecular weight of 25 kDa.
  • the bioluminescence was measured in the IVIS spectrometer with an exposure time of 3 minutes for 1.5 hours. Then, the plate was put in the incubator for 5 hours and the bioluminescence measured again for 15 min. The same was repeated after 8 h and 22 h. The medium is removed and the cells were washed three times with 100 pL optimem medium. 100 pi Optimem were added and at the fluorescence was measured at 650/ 670 nm on Tecan plate reader. The average background fluorescence was subtracted from the signal.

Abstract

L'invention concerne des compositions et des procédés de surveillance non invasive du traitement intracellulaire d'une biomolécule. Les compositions ont une nouvelle fraction thio-luciférine qui peut être conjuguée à la biomolécule directement ou par l'intermédiaire d'un lieur tel qu'une liaison disulfure, la fraction luminescente (telle que thio-luciférine) ou pro-luminescente (telle que thio-cyanobenzothiazoles) est libérée lors de la réduction de la liaison disulfure lors de l'internalisation cytosolique.
PCT/IB2021/000038 2020-01-28 2021-01-27 Compositions bioluminescentes et leurs utilisations WO2021152393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966946P 2020-01-28 2020-01-28
US62/966,946 2020-01-28

Publications (1)

Publication Number Publication Date
WO2021152393A1 true WO2021152393A1 (fr) 2021-08-05

Family

ID=75143673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/000038 WO2021152393A1 (fr) 2020-01-28 2021-01-27 Compositions bioluminescentes et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2021152393A1 (fr)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMELÍA EIRÍKSDOTTIR ET AL: "Cellular Internalization Kinetics of (Luciferin-)Cell-Penetrating Peptide Conjugates", BIOCONJUGATE CHEMISTRY, vol. 21, no. 9, 15 September 2010 (2010-09-15), pages 1662 - 1672, XP055054699, ISSN: 1043-1802, DOI: 10.1021/bc100174y *
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KOVÁCS ANITA K ET AL: "Synthesis ofN-Peptide-6-Amino-d-Luciferin Conjugates with Optimized Fragment Condensation Strategy", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, SPRINGER-VERLAG, DORDRECHT, NL, vol. 25, no. 3, 22 September 2018 (2018-09-22), pages 1209 - 1215, XP036855195, ISSN: 1573-3149, [retrieved on 20180922], DOI: 10.1007/S10989-018-9768-8 *
WENDER P. A. ET AL: "Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 25, 19 June 2007 (2007-06-19), US, pages 10340 - 10345, XP055794576, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.pnas.org/content/pnas/104/25/10340.full.pdf> DOI: 10.1073/pnas.0703919104 *

Similar Documents

Publication Publication Date Title
CN113045660B (zh) 与cd8的抗原结合构建体
US8956825B2 (en) Intranuclear protein transduction through a nucleoside salvage pathway
ES2647823T3 (es) Anticuerpos anti-CD100 y métodos de uso de los mismos
JP6223962B2 (ja) トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット
ES2547016T3 (es) Direccionamiento de ABCB5 para terapia para el cáncer
JP2021530987A (ja) 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
CN105555803B (zh) 制瘤素m受体抗原结合蛋白
EA020465B1 (ru) ИЗОЛИРОВАННЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ErbB3, НАБОРЫ И КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И ИХ ПРИМЕНЕНИЕ
TW200927172A (en) Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
CN109311996B (zh) 抗体、其用途及其缀合物
JP6970090B2 (ja) Ｃ末端リジンで結合体化された免疫グロブリン
HUE034119T2 (en) Chlorotoxin polypeptides and conjugates and their use
JP2021530436A (ja) Ａｘｌを標的とする抗体および抗体−薬物複合体ならびにその製造方法と使用
TWI726217B (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
CN110049999A (zh) 抗psma抗体、其用途及其缀合物
JP2022507294A (ja) Ｃｄｃｐ１－標的化療法
KR20220053577A (ko) 항원 결합 단백질 작제물 및 이의 용도
WO2021152393A1 (fr) Compositions bioluminescentes et leurs utilisations
US8512704B2 (en) Tmem27 antibody
CN108290952B (zh) 用于抑制癌症干细胞的组合物和方法
CN110475779A (zh) 标记含醛靶分子的方法
Yamatsugu et al. Antibody mimetic drug conjugate manufactured by high-yield Escherichia coli expression and non-covalent binding system
CN116249547A (zh) 脑特异性血管生成抑制剂1(bai1)抗体及其用途
US20230012213A1 (en) Novel conjugation chemistry for catalytic antibody 38c2
Feng One-Bead One-Compound Combinatorial Technology as Enabling Tool for Site-Specific Derivatization of Immunoglobulins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21713734

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21713734

Country of ref document: EP

Kind code of ref document: A1